



(51) International Patent Classification:

A61K 38/48 (2006.01) *C12Q 1/6883* (2018.01)
A61K 9/19 (2006.01) *G01N 33/53* (2006.01)
A61P 3/10 (2006.01) *A61B 5/103* (2006.01)

(21) International Application Number:

PCT/US2025/013869

(22) International Filing Date:

30 January 2025 (30.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/626,954 30 January 2024 (30.01.2024) US

(71) Applicant: **DIAMEDICA THERAPEUTICS, INC.**

[US/US]; 301 Carlson Parkway, Suite 210, Minneapolis,
Minnesota 55305 (US).

(72) Inventors: **WAMBEKE, David**; c/o DiaMedica Therapeu-

tics, Inc., 301 Carlson Parkway, Suite 210, Minneapolis,
Minnesota 55305 (US). **PAULSON, Nick**; c/o DiaMedica
Therapeutics, Inc., 301 Carlson Parkway, Suite 210, Min-
neapolis, Minnesota 55305 (US). **PAULS, Rick**; c/o Di-

aMedica Therapeutics, Inc., 301 Carlson Parkway, Suite
210, Minneapolis, Minnesota 55305 (US).

(74) Agent: **ROGEL, Mark E.** et al.; Cooley LLP, 1299 Penn-
sylvania Ave., NW, Suite 700, Washington, District of Co-
lumbia 20004 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: TISSUE KALLIKREIN-1 FOR TREATING PREGNANCY DISORDERS




FIG. 3

(57) Abstract: Provided are methods and compositions for using tissue kallikrein-1 (KLK1) to treat or prevent pregnancy disorders such as fetal growth restriction (FGR) and preeclampsia.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*